- Investopedia•2 days ago
Amgen expects to launch the monthly-dose version of the cholesterol drug in the EU later this year.
- Motley Fool•8 days ago
News that Amgen's Repatha lowers the risk of major cardiovascular events could clear the way for this medicine to achieve billion-dollar blockbuster status.
- Zacks•9 days ago
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
REGN : Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||358.32 x 100|
|Ask||358.90 x 100|
|Day's Range||355.00 - 360.05|
|52 Week Range||325.35 - 452.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||46.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|